Check the time stamp on this data. Updated AI-Generated Signals for Equifax Inc. (EFX) available here: EFX. Type a few ...
Akero Therapeutics reports a 39% improvement in cirrhosis patients using EFX. See why AKRO stock is soaring with the ...
Analysts have been eager to weigh in on the Industrial Goods sector with new ratings on Airbus Group SE (EADSF – Research Report) and Equifax ...
Shares of Equifax Inc. EFX shed 2.64% to $267.52 Monday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index SPX falling 0.76% to 5,994.57 and Dow ...
Zacks.com on MSN5d
AKRO Stock Doubles in a Week as Lead Drug Meets Goal in MASH StudyAkero stock soars 106% in a week following initial positive top line 96-week data from a mid-stage MASH study of its lead ...
We recently compiled a list of the 5 Stocks That Started The Year On A High. In this article, we are going to take a look at ...
Akero Therapeutics announced statistically significant results from a Phase 2b trial of efruxifermin this week, a fibroblast ...
Akero's SYMMETRY Phase 2b study showed 50mg EFX achieved 24% cirrhosis reversal in MASH patients, with improvements in liver ...
There are a few key trends to look for if we want to identify the next multi-bagger. Amongst other things, we'll ...
Oakmark Funds, advised by Harris Associates, released its “Oakmark Equity and Income Fund” fourth quarter 2024 investor letter. A copy of the letter can be downloaded here. The fund delivered -0.20% ...
Shares of Equifax Inc. EFX slid 1.28% to $274.78 Friday, on what proved to be an all-around grim trading session for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback